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Abstract
 .Non-enzymatic glycosylation or glycation of proteins to form advanced glycation endproducts AGE has been proposed
as a process which provides a signal for the degradation of proteins. Despite this, the AGE which act a recognition factor
for receptor-mediated endocytosis and degradation of glycated proteins by monocytes and macrophages has not been
identified. Methylglyoxal, a reactive a-oxoaldehyde and physiological metabolite, reacted irreversibly with arginine
 .  .residues in proteins to form N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithine and N - 5-methyl-4-imidazolon-2-yl ornithined d
 .residues. Human serum albumin minimally-modified with methylglyoxal MG -HSA was bound by cell surface receptorsmin
of human monocytic THP-1 cells in vitro at 48C: the binding constant K value was 377"35 nM and the number ofd
5  .  .receptors per cell was 5.9"0.2=10 ns12 . N -Acetyl-N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithine displaceda d
 .MG -HSA from THP-1 cells, suggesting that the N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithine residue was themin d
receptor recognition factor. At 378C, MG -HSA was internalised by THP-1 cells and degraded. Similar binding andmin
degradation of human serum albumin modified by glucose-derived AGE was found but only when highly modified.
MG -HSA, therefore, is the first example of a protein minimally-modified by AGE-like compounds that binds specificallymin
to monocyte receptors. The irreversible modification of proteins by methylglyoxal is a potent signal for the degradation of
 .proteins by monocytic cells in which the arginine derivative, N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithine, is thed
receptor recognition factor. This factor is not present in glucose-modified proteins.
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1. Introduction
The formation of advanced glycation endproducts
 .AGE by the degradation of glucose-modified pro-
teins was originally proposed as ‘a specific signal for
recognition and degradation of senescent macro-
w xmolecules’ 1 . The formation of AGE in vivo has
been linked to the development of chronic clinical
complications associated with diabetes mellitus —
w xretinopathy, neuropathy and nephropathy 2 , cataract
w x w x3 , macrovascular disease 4 and amyloidosis associ-
ated with Alzheimer’s disease and chronic renal dial-
w xysis 5,6 . Proteins highly-modified with glucose-de-
rived AGE underwent receptor-mediated endocytosis
by monocytes, macrophages and endothelial cells in
vitro, stimulating monocyte chemotaxis and
transendothelial movement, proliferation of
macrophages, and chemotaxis and angiogenesis of
w xhuman endothelial cells 7–9 . Serum albumins
highly-modified by glucose-derived AGE had modi-
w xfied lysine and arginine residues 10 . Glucose-de-
rived AGE compounds derived from lysine and argi-
nine residues have been characterised: N -carboxy-e
w x w xmethyl-lysine 11 , N -lactatolysine 12 , pentosidinee
w x w x13 and pyrraline 14 . None of these, however, have
been found to be recognition factors for receptor-
w xmediated endocytosis 15,16 , and such factors have
proven elusive.
Studies of protein glycation have focused on the
reaction of aldoses and ketoses with lysine residues
in proteins which sequentially form Schiff’s base
adducts, ketoamines or Amadori products fructosa-
. w xmine and AGE 1,11,12,14 . It has recently become
clear that arginine residues are also important sites of
irreversible modification in glycated proteins. The
physiological modifying agents are a-oxoaldehydes
formed from the degradation of Amadori products
w xand elsewhere 10 . Methylglyoxal, a reactive a-
oxoaldehyde and physiological metabolite, is formed
from triose phosphates, acetone in ketone body
metabolism and aminoacetone in the catabolism of
w xthreonine 17 . Methylglyoxal reacts with proteins
initially by reversible reactions with arginine, lysine
and cysteine residues. The major irreversible modifi-
cation of proteins by methylglyoxal occurs on argi-
nine residues, forming N - 5-hydro-5-methyl-4-im-d
. idazolon-2-yl ornithine and N - 5-methyl-4-imidazo-d
. w xlon-2-yl ornithine residues 18,19 . The concentration
of methylglyoxal in blood samples was increased 5-
to 6-fold in diabetic patients and the detoxification of
w xmethylglyoxal by the glyoxalase system 17 was
w xlogistically-linked to diabetic complications 20 ,
where increased formation and degradation of meth-
ylglyoxal-modified proteins may be involved. Bovine
serum albumin highly-modified with glucose-derived
AGE 40 lysine residues and 14 arginine residues
. modified and with methylglyoxal 23 lysine residues
. w xand 21 arginine residues modified 21 were bound
by cell surface receptors on P388D macrophages,1
w xinternalised and degraded by lysosomal enzymes 22 .
Such highly-modified proteins, however, are unlikely
w xto be present in vivo 23 . Recent research found
molecular mass changes of human serum albumin
 .HSA in vivo consistent with 0–1 glucose residue
per protein molecule in normal healthy control sub-
jects and 2–3 glucose residues in diabetic patients
w xwith good glycaemic control 24 . It is therefore
appropriate to study the receptor binding competence
of HSA with 2–3 methylglyoxal and glucose moi-
eties per protein molecule, MG -HSA and AGE -min min
HSA, respectively.
We now report that proteins minimally-modified
with methylglyoxal were bound by cell surface recep-
tors of human monocytic THP-1 cells in vitro, inter-
nalised and degraded but proteins minimally-mod-
ified with glucose-derived AGE were not. The irre-
versible modification of proteins by methylglyoxal
was a potent signal for the degradation of proteins by
monocytic cells and the N - 5-hydro-5-methyl-4-im-d
.idazolon-2-yl ornithine residue is the suggested re-
ceptor recognition factor involved in this process.
MG -HSA, therefore, is the first example of amin
protein minimally-modified by AGE-like compounds
that binds specifically to monocyte receptors.
2. Materials and methods
2.1. Materials
Human monocytic leukaemia THP-1 cells were
purchased from the European Collection of Animal
 .Cell Cultures Porton Down, Wilts., UK . RPMI
1640 medium and fetal calf serum were purchased
 .from Gibco BRL Paisley, Scotland . Human serum
 .albumin HSA , human prothrombin, SIGMA-
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 .COTEe silicone solution in heptane and methyl-
glyoxal dimethylacetal were purchased from Sigma
 . w125 xChem. Co. Poole, Dorset, UK . Sodium I iodide
100 mCirml, in sodium hydroxide solution, pH
. w14 x  .7–11 and 1- C glucose 10 mCirmmol were pur-
chased from Amersham Life Sciences Amersham,
.Buckinghamshire, UK . Lactoperoxidaserglucose ox-
idase solid phase Enzymobeadse were purchased
 .from BioRad Hemel Hempstead, Hertfordshire, UK .
Exocellulosee GF-5 disposable gel filtration columns
 .were purchased from Pierce Chester, UK . High
purity methylglyoxal was prepared from methylgly-
w xoxal dimethylacetal as described 25 .
2.2. Preparation and characterisation of N -acetyl-a( )N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithine andd ( )N -acetyl-N - 5-methyl-4-imidazolon-2-yl ornithinea d
N -Acetyl-N - 5-hydro-5-methyl-4-imidazolon-2-a d
.yl ornithine was prepared by incubation of N -a
 .  .acetylarginine 16.7 mM and methylglyoxal 20 mM
 .in sodium phosphate buffer 200 mM, pH 7.4; 30 ml
for 7 days at 378C and lyophilized to dryness. The
 .residue was extracted with methanol 50 ml , the
methanol removed in vacuo and the residual solid
product purified by reversed phase HPLC. The col-
 .umn was Nova-Pake octadecylsilica ODS cartridge
 . 2.5 cm=10 cm fitted with a pre-column 2.5 cm=
.1 cm in a Waters 25=10 radial compression unit.
The mobile phase was 500 mM potassium phosphate
buffer, pH 7.4, the flow rate 9.9 mlrmin, the sample
was 10 mg in 0.1 ml of mobile phase, and the eluate
absorbance was monitored at 225 nm. A major peak
was collected of retention time 5.7 min the dead
.time was 3.0 min , lyophilized, extracted with
 .methanol 1=40 ml; 2 =20 ml and the methanol
removed in vacuo to yield 33 mg of product. 1H-
 .NMR d ppm and J Hz; 270 MHz; D O :H Hx,Hy 2
 .  .acetyl Me 3H 2.00; ornithinyl 2-H 2H , 4.12; 3-H
 .  .  . and 4-H 4H 1.50–1.90 m ; 5-H 2H , 3.24 t; Js
.  .5.5; A,B, 58% and 3.32 t; Js5.8; C, 42% ; imida-
 .  .  .zolonyl 5-methyl 3H 1.32 d; Js6.81 , 5-H 1H
 . 13 4.14 m . C-NMR d ppm; 68 MHz proton decou-C
.pled; D O : acetyl Me 21.2, CO 160.3; ornithinyl2
 .  .C-1 172.9, C-2 54.1, C-3 28.1, C-4 24.1 A 24.0 B
 .  .  .  .24.9 C , C-5 40.3 A 40.1 B 41.2 C ; imidazolonyl
 .  .  .  .C-2 154.5 A 167.5 B,C , C-4 178.3 A 178.0 B,C ,
 .  .  .  .C-5 56.6 A 55.9 B 51.6 C , 5-Me 15.8 A,C
 .17.2 B . A, B and C relate d and J values to
 .tautomeric forms shown Fig. 2a . FAB mass spec-
 .trometry gave an Mq1 peak of Mq1 rzs271.
 .N -Acetyl-N - 5-methyl-4-imidazolon-2-yl ornithinea d
was prepared and characterised as previously de-
w x  .scribed 19 . Briefly, N -acetylarginine 20 mM wasa
 .incubated with methylglyoxal 20 mM in 200 mM
sodium phosphate buffer, pH 7.4 and 378C, under
aseptic conditions for 14 days, with adjustment of pH
 .to 7.4 with sodium hydroxide solution 5 M as
required. The reaction mixture was then lyophilised
 .to dryness and extracted with ethanol 5=20 ml .
The solid obtained after evaporation of ethanol in
vacuo was reconstituted in 50 mM acetic acid 1.5
.ml and the product purified by preparative reversed
phase HPLC as described above except the mobile
phase was 50 mM acetic acid with a flow rate of 6
mlrmin and the eluate was monitored at 350 nm.
The eluate fraction 126–150 ml was collected and
lyophilised to dryness and the residual solid charac-
1  . 13 terized by H-NMR 270 MHz and C NMR 68
.MHz spectroscopy and FAB mass spectrometry
 . w xglycerol matrix 19 . The purity of the imidazolones
was investigated by analytical reversed phase HPLC
ODS cartridge 0.8 cm=10 cm with pre-column in a
Waters 8=10 radial compression unit, mobile phase
20 mM trifluoroacetic acid with 0–50% methanol
from 5–25 min, flow rate 2 mlrmin, injection vol-
.ume 10 ml, eluate absorbance 225 nm . Retention
 . times min were: N -acetyl-N - 5-hydro-5-methyl-4-a d
. imidazolon-2-yl ornithine 3.9 and N -acetyl-N - 5-a d
.methyl-4-imidazolon-2-yl -ornithine 17.4.
2.3. Preparation and characterization of proteins
modified by methylglyoxal and glucose-deri˝ed ad-
˝anced glycation endproducts
HSA and prothrombin minimally-modified by
 .methylglyoxal MG -HSA and MG -Pr were pre-min min
 .pared by incubation of the protein 100 mM in
 .sodium phosphate buffer 100 mM, pH 7.4 and 378C
with 500 mM methylglyoxal for 24 h, dialysis of the
modified protein against ammonium bicarbonate
 .buffer 30 mM, pH 7.9 and 48C and lyophilisation to
dryness. HSA partially-modified with methylglyoxal
 .MG -HSA was prepared similarly by incubationpart
of 100 mM HSA with 100 mM methylglyoxal for 24
h. HSA minimally-modified by glucose-derived AGE
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 .AGE -HSA was prepared by incubation of HSAmin
 . 50 mgrml in sodium phosphate buffer 150 mM,
.pH 7.4 and 378C , with 50 mM b-D-glucose for 5
weeks. HSA highly-modified with glucose-derived
 .AGE AGE-HSA was prepared as previously de-
w xscribed 10 . The AGE-modified HSA derivatives
were dialyzed and lyophilized as described above.
Unmodified proteins were processed similarly for
receptor binding control experiments. The modifica-
tion of amino acid residues in methylglyoxal and
AGE-modified proteins was investigated as described
w x10 . The extent of modification in proteins mini-
mally-modified by methylglyoxal and glucose-de-
rived AGE was determined by preparation of the
w14 x w xmodified proteins with 2- C methylglyoxal 26 and
w14 x1- C glucose and assay of specific radioactivity
content in the dialyzed protein by scintillation count-
ing and the Lowry assay for protein using the un-
.modified protein as standard .
2.4. Receptor-mediated endocytosis of modified pro-
teins by THP-1 cells
THP-1 cells, seeding density 1=105 cellsrml,
were cultured for 4–5 days in RPMI 1640 medium
containing 20% fetal calf serum under an atmosphere
w xof 5% CO in air with 100% humidity 27 . MG -2 min
HSA, AGE -HSA and AGE-HSA were labelledmin
w xwith 125-iodine as described 22 and had specific
activities of 7–14 000 cpm per ng of protein. For
 6.receptor binding studies, THP-1 cells 2=10 were
incubated in RPMI 1640 with 2 nM–1 mM of
w125 xI modified protein in RPMI 1640 with 3% HSA
 .final volume 100 ml for 5–120 min at 48C. Cells
 .were sedimented by centrifugation 2,300 g, 30 s ,
washed three times with 1.0 ml aliquots of RPMI
1640 with 3% HSA and finally counted LKB 1260
.Multigamma counter . AGE-HSA was bound non-
specifically to the walls of incubation tubes; hence,
all binding experiments of AGE-HSA to THP-1 cells
were performed with sample tubes and pipette tips
w xpre-coated with SIGMACOTEe 28 . Endocytosis
and degradation of MG -HSA and AGE-HSA bymin
THP-1 cells was investigated by incubation of THP-1
cells with 250 nM modified protein for 0–120 min at
378C. After the incubation period, the cells were
sedimented by centrifugation, the supernatant re-
moved and retained. The cell pellet was washed three
times in RPMI 1640 at 48C and counted. An aliquot
 .  .50 ml of supernatant was diluted with 3% wrv
 .  .HSA in RPMI 1640 50 ml , ice-cold 20% wrv
 .trichloroacetic acid 100 ml added and the sample
held on ice for 20 min. The precipitate was sedi-
 .mented by centrifugation 10 000=g, 1 h and an
 .aliquot 100 ml of the supernatant counted as a
measure of the degraded modified protein. Data of
the dependence of MG -HSA and AGE-HSA bind-min
w xing to THP-1 cells was analysed as described 22 .
3. Results
3.1. Extent of modification of proteins by methylgly-
oxal and glucose-deri˝ed AGE in MG -HSA,min
MG -HSA, MG -Pr, AGE -HSA and AGE-HSApart min min
At low concentration, methylglyoxal selectively
w xmodified arginine residues in proteins 10 . Analysis
of arginine residues in MG -HSA by derivatisationmin
with 9,10-phenanthrenequinone indicated that there
 .were 22.6"0.9 residual arginine residues ns12 ,
and therefore there were 1.4 modified arginine
residues per MG -HSA molecule; amino acid anal-min
ysis gave 22.1"1.5 residual arginine residues, indi-
cating there were 1.9 arginine residues per MG -min
 .HSA molecule ns3 . Preparation of MG -HSAmin
w14 xwith 2- C methylglyoxal indicated the presence of
2.4"0.3 methylglyoxal residues per molecule of
MG -HSA. Amino acid analysis with acid hydroly-min
w xsis or enzymatic hydrolysis, as described 10,29 ,
indicated there was no detectable modification of
lysine -1 lysine residue modified per protein
.molecule in MG -HSA. From the estimates ofmin
unmodified arginine residues and extent of modifica-
tion, the modification of lysine may be in the range
0.5–1.0 residues per MG -HSA molecule. From themin
kinetics of reaction of methylglyoxal with HSA stud-
w xied previously 10 , the predicted extent of lysine
modification is ca. 0.3 residues per MG -HSAmin
 .molecule — which may be N - 1-carboxyethyl -lysinee
w x w x30 , 4-methylimidazolysine 31 and other residues.
There is expected to be minor modification of lysine
residues in MG -HSA. The role of these modifica-min
tions in receptor binding cannot be excluded but
evidence of binding via the modified arginine residues
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— see below, suggests that lysine adducts are not
required.
w14 xPreparation of MG -Pr with 2- C methyl-min
glyoxal indicated the presence of 4.1"0.1 methyl-
 .glyoxal moieties per molecule of MG -Pr ns3 .min
Similar preparation of MG -HSA indicated thatpart
there were 0.47"0.05 methylglyoxal moieties per
 .molecule of MG -HSA ns3 . Preparation ofpart
w14 xAGE -HSA with 1- C glucose indicated the pres-min
ence of 1.94"0.15 glucose residues per molecule of
 .AGE -HSA ns3 . Amino acid analysis of AGE-min
HSA indicated that there were 20 lysine residues and
16 arginine residues modified by glucose-derived
w xAGE per molecule of AGE-HSA 10 . Glucose-de-
rived AGE-modified HSAs prepared by these meth-
ods have been shown by immunoassay and chromato-
graphic assays after hydrolysis to contain N -e
w x w xcarboxymethyl-lysine 32 , pentosidine 33 and
w xpyrraline 14 .
3.2. Binding of proteins minimally-modified by meth-
ylglyoxal to THP-1 cells at 48C
When 250 nM MG -HSA was incubated withmin
THP-1 cells at 48C, there was a rapid association of
MG -HSA with THP-1 cells which maximised aftermin
90 min at ca. 1.0 pmol of MG -HSA bound per 2=min
6  .10 THP-1 cells Fig. 1a . There was no specific
binding of AGE -HSA to THP-1 cells, however —min
the binding was unsaturable and non-specific — data
not shown. From a study of the dependence of the
binding of MG -HSA to THP-1 cells on the concen-min
tration of MG -HSA, corrected for non-specificmin
binding, the dissociation constant K value was 377d
"35 nM and the receptor number R value wasT
5  .5.9"0.2=10 per cell ns12 — Fig. 1b. The
binding of MG -HSA was not competitive withmin
HSA and AGE-HSA but was competitive with
MG -Pr and MG -HSA — Table 1. This indi-min part
cates that one methylglyoxal-modified group per pro-
tein molecule was sufficient to confer binding compe-
tence — there being very little MG -HSA withpart
)1 methylglyoxal residue per molecule, and that
receptor binding competence was not specific to
methylglyoxal-modified serum albumin.
The possible prospective recognition factors for
the binding of MG -HSA to THP-1 cells, imida-min
zolone derivatives of arginine residues, were prepared
and characterised as model ligands of N -a
acetylarginine: N -acetyl-N - 5-methyl-4-imidazolon-a d
Fig. 1. Binding of MG -HSA to THP-1 cells. a. Time-course of the binding of 250 nM MG -HSA to THP-1 cells. Data aremin min
mean"S.E.M. of 3 determinations. b. Concentration dependence of the binding of MG -HSA to THP-1 cells after incubation for 60min
 .  .min at 48C in the absence I and presence B of 30 mM MG -HSA. A Scatchard plot is given inset.min
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Table 1
Effect of competitor ligands on the binding of MG -HSA and AGE-HSA to THP-1 cells in vitromin
Radiolabelled ligand Competitor ligand MG -HSAmin Bound
 .  .pmol mean"S.E.M. ns3
 .MG -HSA 250 nM None 1.00"0.02min
 .AGE-HSA 0.5 mM 0.94"0.07
 ." 1.0 mM 0.99"0.03
 ." 3.0 mM 0.93"0.13
 ." 5.0 mM 0.95"0.06
 .  .MG -Pr 2.0 mM 0.90"0.03 P-0.05min
 .  ." 5.0 mM 0.73"0.04 P-0.01
 .MG -HSA 2.0 mM 0.83"0.05Part
 .  ." 5.0 mM 0.81"0.03 P-0.01
 .N -acetyl-N - 5-methyl-4- imidazolon-2-yl - 0.99"0.04a d
 .ornithine 20 mM
Radiolabelled ligand Competitor ligand AGE-HSA Bound
 .  .pmol mean"S.E.M. ns3
 .AGE-HSA 250 nM None 2.21"0.11
 .MG -HSA 0.5 mM 2.08"0.10min
 ." 1.0 mM 2.07"0.22
 ." 3.0 mM 2.12"0.06
 ." 5.0 mM 1.85"0.15
 .Fig. 2. Competitive binding of MG -HSA and N -acetyl-N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithine to THP-1 cells. a. Irre-min a d
versible adducts of methylglyoxal with arginine residues — synthetic ligands of N -acetylarginine. b. Competitive binding ofa
 .MG -HSA and N -acetyl-N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithine to THP-1 cells. THP-1 cells were incubated for 60 min atmin a d
w125 x  .48C with 250 nM I MG -HSA and 0-50 mM N -acetyl-N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithine. Data are mean"S.E.M.min a d
of 3 determinations.
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. w x2-yl ornithine, as previously described 19 , and N -a
 .acetyl-N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithined
— which gave 1H- and 13C-NMR spectra consistent
with its existence in the 3 forms — the 2-aminoalkyl-
5-hydro-4-imidazolones, A and B, representing ca.
58% and the 2-iminoalkyl-4-imidazolidinone C, rep-
 . resenting ca. 42% Fig. 2a . N -Acetyl-N - 5-methyl-a d
.  .4-imidazolon-2-yl ornithine 20 mM did not com-
pete for binding with 250 nM MG -HSA to THP-1min
cells — Table 1. Indeed, it was present in MG -min
HSA in only trace amounts since it was formed only
slowly in methylglyoxal-modified proteins and
MG -HSA lacked the characteristic fluorescencemin
associated with N - 5-methyl-4-imidazolon-2-d
. w x yl ornithine residues 10 . N -Acetyl-N - 5-hydro-5-a d
.  .methyl-4-imidazolon-2-yl ornithine 1–50 mM ,
however, competed with MG -HSA for binding tomin
 .receptors on THP-1 cells Fig. 2b when present at
4–200 times the concentration of MG -HSA. How-min
ever, given that N -acetyl-N - 5-hydro-5-methyl-4-a d
.imidazolon-2-yl ornithine is a non-protein ligand and
that the closely related analogue N -acetyl-N - 5-a d
.methyl-4-imidazolon-2-yl ornithine showed no simi-
lar displacement of MG -HSA from cell surfacemin
receptors, this indicates that the N - 5-hydro-5-d
.methyl-4-imidazolon-2-yl ornithine residue was
bound by specific receptors and is a critical residue
for receptor recognition in N -acetyl-N - 5-hydro-5-a d
.methyl-4-imidazolon-2-yl ornithine and also in
MG -HSA.min
3.3. Binding of human serum albumin highly-mod-
ified with glucose-deri˝ed ad˝anced glycation end-
products by THP-1 cells at 48C
AGE-HSA was bound by cell surface receptors on
THP-1 cells but was also bound significantly to the
walls of the plastic tubes used in the incubations. A
study of the binding of AGE-HSA to THP-1 cells
with tubes and pipette tips coated with SIGMA-
w xCOTEe 28 indicated that the binding of AGE-HSA
to THP-1 cells at 48C was maximised after 60 min
where there was ca. 2.3 pmol of AGE-HSA bound
6  .per 2=10 THP-1 cells Fig. 3a . From a study of
the dependence of the binding of AGE-HSA to THP-1
cells on the concentration of AGE-HSA, corrected for
non-specific binding, the dissociation constant Kd
value was 449"52 nM and the total receptor num-
6  .ber R value was 1.2"0.01=10 per cell ns7T
— Fig. 3b. Binding of AGE-HSA to THP-1 cells was
not competitive with MG -HSA — Table 1.min
Fig. 3. Binding of AGE-HSA to THP-1 cells at 48C. a. Time-course of the binding of 250 nM AGE-HSA to THP-1 cells. Data are
mean"S.E.M. of 3 determinations. b. Concentration dependence of the binding of AGE-HSA to THP-1 cells after incubation for 60 min
 .  .in the absence I and presence B of 30 mM AGE-HSA. A Scatchard plot is given inset.
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Fig. 4. Binding and degradation of MG -HSA and AGE-HSA by THP-1 cells at 378C. Cell association and degradation of MG -HSA:min min
 .  .  .  .  .  . .a cell associated B ; b extracellular degraded I . Cell association and degradation of AGE-HSA: c cell associated B , d
 .extracellular degraded I . Data are mean"S.E.M. of 3 determinations. Incubations were performed as described in Section 2.
3.4. Binding and degradation by THP-1 cells of
human serum albumin minimally-modified by methyl-
glyoxal and highly-modified by glucose-deri˝ed ad-
˝anced glycation endproducts at 378C
At 378C, MG -HSA and AGE-HSA were rapidlymin
bound by the THP-1 cells in the initial 5 min of
incubation and decreased during the remainder of the
 .120 min incubation period Fig. 4a and c . Degrada-
tion products of MG -HSA and AGE-HSA, asmin
judged by trichloroacetic acid soluble fragments in
the extracellular medium, appeared after 5 min of the
incubation and increased during the remainder of the
 .120 min incubation period Fig. 4b and d .
4. Discussion
Human promonocytic leukaemia THP-1 cells pro-
vide a convenient monocytic cell model for studying
receptor-mediated endocytosis of oxidised and gly-
cated proteins. The monocytic nature of THP-1 cells
was characterized by the presence of a-naphthyl
butyrate esterase, expression of lysozyme, phago-
cytosis of latex particles and immunoglobulin G-
coated sheep erythrocytes. THP-1 cells have Fc and
C3b receptors but no cytoplasmic immunoglobulins
w x27 . THP-1 cells bound and degraded native human
 .low density lipoprotein LDL via the LDL-receptor
pathway but did not bind acetyl-LDL. Differentiated,
macrophage-like THP-1 cells, however, acquired the
ability to specifically degrade acetyl-LDL and lost
the ability to degrade native LDL, indicating the
induction of scavenger receptor activity in differenti-
ated THP-1 cells; the K value of acetyl-LDL ford
cell surface receptors of differentiated THP-1 cells
was 8 nM and there were approximately 1500 recep-
w xtors per cell. 34 . THP-1 cells differentiated by phor-
 .bol-12-myristate-13-acetate PMA expressed both
w xscavenger receptors type I and type II 35 . Recently,
a 120 kDa cell surface receptor in undifferentiated
THP-1 cells that binds oxidised LDL has been identi-
w x  .fied 36 . Bovine serum albumin BSA highly-mod-
ified with glucose-derived AGE was bound and de-
graded by differentiated THP-1 cells; the K valued
w xwas 460 nM 21 . Binding was inhibited competi-
tively by the aldehyde-modified proteins, formal-
dehyde-modified BSA and glycolaldehyde-modified
BSA. Receptor binding activity in differentiated
THP-1 cells was not produced by reduction of BSA-
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glucose Schiff’s base adducts with NaBH , and it4
was not lost from AGE-BSA by reduction with
NaBH , indicating that the receptor binding activity4
was not associated with hexitol-lysyl residues and
was not destroyed by NaBH . Receptor-mediated4
endocytosis of AGE-BSA was increased by differen-
tiation. In this study, we found a similar affinity and
activity of AGE-HSA for undifferentiated THP-1
cells, suggesting that receptors for proteins modified
by AGE are expressed in THP-1 cells. Therefore, the
binding of AGE-modified proteins is not only associ-
w xated with the scavenger receptors 37,38 .
AGE-HSA is particularly suited to binding scav-
enger receptors since it has a marked increase in net
negative charge produced by the high extent of modi-
w xfication by glucose-derived AGE 10 . Recent reports,
however, have drawn attention to the prevalence of
non-specific binding in the interaction of AGE-mod-
w xified proteins with macrophages and monocytes 28
and the extent of modification of proteins by AGE in
w xvivo 24 . It was therefore pertinent to investigate the
receptor-mediated endocytosis of AGE -HSA bymin
THP-1 cells. The lack of specific binding of AGE -min
HSA to THP-1 cells was in agreement with previous
work using other monocyte-macrophage cell lines
w x28 .
The binding of proteins minimally-modified with
methylglyoxal by monocytic THP-1 cells suggested
that this modification may be particularly important
as a signal for protein degradation in vivo, where the
 .N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithined
residues is the recognition factor. N - 5-Hydro-4-im-d
.idazolon-2-yl ornithine derivatives may also be
formed from other a-oxoaldehydes present in physio-
logical systems — for example, 3-deoxyglucosone
w x39 . This may lead to similar receptor-mediated en-
docytosis of analogous minimally-modified proteins
w x38 . In MG -HSA, the major irreversible modifica-min
tion occurs on arginine residues, forming mainly
 .N - 5-hydro-5-methyl-4-imidazolon-2-yl ornithined
w xresidues 10,18,19 — and this may provide the
recognition factor for receptor binding, and presum-
ably subsequent induction of the synthesis and secre-
tion of cytokines. In glucose-modified proteins, most
modification occurs initially on lysine and N-terminal
amino groups to form fructosamine which degrades
to the AGE compound, N -carboxymethyl-lysinee
w x10,40,41 . A further minor product of fructosamine
degradation, however, is the a-oxoaldehyde 3-de-
oxyglucosone which may react with arginine residues
to produce similar imidazolone adducts to those
w xformed by methylglyoxal 39 . The imidazolone
adducts in AGE-HSA may be the pharmacophore for
induction of functional responses such as cytokine
synthesis but their decreased formation may explain
why AGE -HSA does not bind specifically to cellmin
surface receptors. This may be overcome by increas-
ing the extent of modification of HSA to form AGE-
HSA but leads to the presence of relatively high
concentrations of N -carboxymethyl-lysine residues,e
conferring a marked increase in net negative charge
and directing AGE-HSA to scavenger-like receptors
w x37,38 . The identities of the receptors binding
MG -HSA and AGE-HSA in THP-1 cell are notmin
known but the receptor for AGE, RAGE, complex
w x w x42 and other receptors 36 may be involved. This
remains to be investigated.
When THP-1 cells were incubated with MG -min
HSA and AGE-HSA at 378C, there was a rapid
association of the proteins with THP-1 cells in the
initial 5 minutes of the incubation and then a gradual
decrease to a steady state level. This may be due to
rapid internalisation of cell-associated modified pro-
teins. Degradation products of both MG -HSA andmin
AGE-HSA appeared in the extracellular medium after
5 min and increased thereafter. Both MG -HSA andmin
AGE-HSA activated the synthesis and secretion of
interleukin-1b , tumour necrosis factor-a and
macrophage colony-stimulating factor in THP-1 cells
w x43–45 which may lead to secretion of proteases and
oxidants, further proteolytic and oxidative modifica-
tion of MG -HSA and AGE-HSA and thereby de-min
creased cell binding.
The modification of proteins by glucose-derived
AGE compounds has been associated with many
w xdisease processes 2–6 where receptor-mediated en-
docytosis of proteins highly-modified with glucose-
derived AGE and induction of functional responses
w xhave been implicated 7–9 . Recent research on the
formation of AGE in endothelial cells cultured under
hyperglycaemic conditions indicated that methylgly-
w xoxal was a major precursor of AGE 46 . The degra-
dation of methylglyoxal-modified proteins by mono-
w xcytes and activation of cytokine synthesis 43–45
may underlie the link of methylglyoxal metabolism
with the development of chronic pathology in dia-
( )M.E. Westwood et al.rBiochimica et Biophysica Acta 1356 1997 84–94 93
w xbetes mellitus 20 , and proteins modified by methyl-
glyoxal and other a-oxoaldehydes may be involved
in disease mechanisms where glucose-derived AGE
w xcompounds have been implicated 2–6 .
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